Non-Relapse | Relapse | Median [CI 95%] (days) | p (Log-Rank) | |||
---|---|---|---|---|---|---|
n | % | N | % | |||
Sample | 32 | 100 | 21 | 100 | 108 [69-NA} | |
Gender | ||||||
Men | 22 | 68.8 | 18 | 85.7 | 104 [68-NA] | 0.16 |
Women | 10 | 31.2 | 3 | 14.3 | NA [58-NA] | |
Age range (years) | ||||||
14-30 | 14 | 43.8 | 14 | 66.7 | 79 [58-NA] | 0.22 |
31-50 | 13 | 40.6 | 4 | 19.0 | 369 [108-NA] | |
≥51 | 5 | 15.6 | 3 | 14.3 | 68 [51-NA] | |
Adverse drugs events (ADE)* | ||||||
Yes | 10 | 31.3 | 2 | 9.5 | NA [58-NA] | 0.20 |
No | 17 | 53.1 | 12 | 57.1 | 108 [68-NA] | |
Duration of primaquine therapy* | ||||||
Short regimen | 19 | 59.4 | 16 | 76.2 | 79 [65-NA] | 0.34 |
Long regimen | 10 | 31.3 | 4 | 19.0 | 218 [104-NA] | |
Primaquine total dose adjusted by weight* | ||||||
Yes (≥ 3.2 mg/kg) | 25 | 78.1 | 12 | 57.1 | 182 [104-NA] | 0.03 |
No (< 3.2 mg/kg) | 5 | 15.6 | 6 | 28.3 | 54 [40-NA] |